

Kristian Reich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/118868/publications.pdf>

Version: 2024-02-01

252
papers

26,078
citations

5896

81
h-index

7160

153
g-index

261
all docs

261
docs citations

261
times ranked

10555
citing authors

#	ARTICLE	IF	CITATIONS
1	Secukinumab in Plaque Psoriasis " Results of Two Phase 3 Trials. New England Journal of Medicine, 2014, 371, 326-338.	27.0	1,675
2	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet, The, 2008, 371, 1675-1684.	13.7	1,296
3	Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet, The, 2005, 366, 1367-1374.	13.7	975
4	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and Tj ETQq0 0.0.rgBT /Overlock 10	13.7	719
5	Definition of treatment goals for moderate to severe psoriasis: a European consensus. Archives of Dermatological Research, 2011, 303, 1-10.	1.9	690
6	European S3"Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 1-70.	2.4	683
7	Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. New England Journal of Medicine, 2016, 375, 345-356.	27.0	670
8	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator"controlled VOYAGE 2 trial. Journal of the American Academy of Dermatology, 2017, 76, 418-431.	1.2	554
9	Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the) Tj ETQq1 1 0.784314 rgBT /Overl	1.2	498
10	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. Journal of the American Academy of Dermatology, 2015, 73, 400-409.	1.2	472
11	Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE) Tj ETQq1 1 0.784314 rgBT /Ove	13.7	428
12	Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. Journal of the American Academy of Dermatology, 2014, 70, 871-881.e30.	1.2	423
13	Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t. British Journal of Dermatology, 2018, 178, 1083-1101.	1.5	380
14	A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. British Journal of Dermatology, 2016, 175, 273-286.	1.5	378
15	Epidemiology and comorbidity of psoriasis in children. British Journal of Dermatology, 2010, 162, 633-636.	1.5	375
16	European S3"Guidelines on the systemic treatment of psoriasis vulgaris " Update 2015 " Short version " " <sc>EDF</sc> in cooperation with <sc>EADV</sc> and <sc>IPC</sc>. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2277-2294.	2.4	353
17	Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5"years of follow-up. British Journal of Dermatology, 2013, 168, 844-854.	1.5	350
18	Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. British Journal of Dermatology, 2009, 160, 1040-1047.	1.5	341

#	ARTICLE	IF	CITATIONS
19	Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. <i>British Journal of Dermatology</i> , 2020, 183, 242-255.	1.5	277
20	A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2015, 373, 136-144.	27.0	270
21	Co-morbidity and Age-related Prevalence of Psoriasis: Analysis of Health Insurance Data in Germany. <i>Acta Dermato-Venereologica</i> , 2010, 90, 147-151.	1.3	265
22	Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 83-98.e4.	1.2	264
23	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 60-69.e9.	1.2	258
24	The concept of psoriasis as a systemic inflammation: implications for disease management. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 3-11.	2.4	253
25	Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. <i>Lancet, The</i> , 2019, 394, 831-839.	13.7	250
26	Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 877-884.	2.9	242
27	Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study in Germany. <i>Dermatology</i> , 2008, 216, 366-372.	2.1	237
28	Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. <i>British Journal of Dermatology</i> , 2015, 173, 930-939.	1.5	236
29	S3 " Guidelines on the treatment of psoriasis vulgaris (English version). Update. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, S1-95.	0.8	235
30	Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. <i>Arthritis Research and Therapy</i> , 2019, 21, 111.	3.5	215
31	Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. <i>Immunology</i> , 2014, 141, 133-142.	4.4	200
32	Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2021, 397, 2169-2181.	13.7	199
33	Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 576-586.	13.7	198
34	Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis. <i>JAMA Dermatology</i> , 2020, 156, 1333.	4.1	194
35	A 52-Week Trial Comparing Briakinumab with Methotrexate in Patients with Psoriasis. <i>New England Journal of Medicine</i> , 2011, 365, 1586-1596.	27.0	182
36	Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. <i>British Journal of Dermatology</i> , 2015, 172, 1371-1383.	1.5	179

#	ARTICLE	IF	CITATIONS
37	Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. <i>British Journal of Dermatology</i> , 2012, 166, 179-188.	1.5	177
38	Bimekizumab versus Secukinumab in Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021, 385, 142-152.	27.0	173
39	Nail psoriasis in Germany: epidemiology and burden of disease. <i>British Journal of Dermatology</i> , 2010, 163, 580-585.	1.5	160
40	Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 683-691.	2.4	159
41	Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). <i>British Journal of Dermatology</i> , 2011, 165, 1109-1117.	1.5	159
42	Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 224-231.	1.2	157
43	Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis. <i>Experimental Dermatology</i> , 2015, 24, 529-535.	2.9	157
44	The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 507-517.	2.4	156
45	Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. <i>British Journal of Dermatology</i> , 2017, 177, 1014-1023.	1.5	155
46	Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 377-388.	1.2	155
47	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2461-2498.	2.4	149
48	Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 473-479.	0.9	143
49	Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. <i>Lancet, The</i> , 2021, 397, 487-498.	13.7	139
50	Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. <i>Lancet, The</i> , 2021, 397, 475-486.	13.7	136
51	Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab ² certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. <i>British Journal of Dermatology</i> , 2012, 167, 180-190.	1.5	131
52	Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and Tj ETQq0 0 0 rgBT / Overlock 1026 of 50 137		
53	Epidemiology and Comorbidity in Children with Psoriasis and Atopic Eczema. <i>Dermatology</i> , 2015, 231, 35-40.	2.1	126
54	Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 742-751.	1.2	124

#	ARTICLE	IF	CITATIONS
55	Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest. Archives of Dermatological Research, 2015, 307, 875-883.	1.9	124
56	A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 438-453.	2.4	122
57	Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. British Journal of Dermatology, 2011, 164, 862-872.	1.5	121
58	Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. British Journal of Dermatology, 2014, 171, 1123-1128.	1.5	120
59	A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blind trial. British Journal of Dermatology, 2020, 182, 1348-1358.	1.5	117
60	Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. British Journal of Dermatology, 2006, 154, 1161-1168.	1.5	116
61	German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Archives of Dermatological Research, 2007, 299, 111-138.	1.9	116
62	European S3-Guideline on the systemic treatment of psoriasis vulgaris " Update Apremilast and Secukinumab " <scp>EDF</scp> in cooperation with <scp>EADV</scp> and <scp>IPC</scp>. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1951-1963.	2.4	116
63	Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations. Journal of the American Academy of Dermatology, 2010, 63, 571-579.	1.2	115
64	Bimekizumab versus Adalimumab in Plaque Psoriasis. New England Journal of Medicine, 2021, 385, 130-141.	27.0	114
65	Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. Journal of the American Academy of Dermatology, 2017, 76, 432-440.e17.	1.2	111
66	Promoter Polymorphisms of the Genes Encoding Tumor Necrosis Factor- α and Interleukin-1 β are Associated with Different Subtypes of Psoriasis Characterized by Early and Late Disease Onset. Journal of Investigative Dermatology, 2002, 118, 155-163.	0.7	110
67	Cost of Moderate to Severe Plaque Psoriasis in Germany: A Multicenter Cost-of-Illness Study. Dermatology, 2006, 212, 137-144.	2.1	109
68	S3 Guideline for the treatment of psoriasis vulgaris, update " Short version part 1 " Systemic treatment. JDDG - Journal of the German Society of Dermatology, 2018, 16, 645-669.	0.8	107
69	Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). Journal of the American Academy of Dermatology, 2017, 77, 855-862.	1.2	104
70	Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase <scp>III</scp> clinical trials (re <scp>SURFACE</scp> 1 and re <scp>SURFACE</scp> 2) through 148 weeks. British Journal of Dermatology, 2020, 182, 605-617.	1.5	103
71	Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 476-485.	2.4	101
72	Approach to managing patients with nail psoriasis. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 15-21.	2.4	100

#	ARTICLE	IF	CITATIONS
73	German S3-guidelines on the treatment of psoriasis vulgaris (short version). Archives of Dermatological Research, 2012, 304, 87-113.	1.9	96
74	Clinical meaningfulness of complete skin clearance in psoriasis. Journal of the American Academy of Dermatology, 2016, 75, 77-82.e7.	1.2	96
75	Wirksamkeit und Sicherheit von Fumarsäureestern in der Langzeittherapie der Psoriasis – Eine retrospektive Studie (FUTURE). JDDG - Journal of the German Society of Dermatology, 2009, 7, 603-611.	0.8	94
76	Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). British Journal of Dermatology, 2013, 168, 1325-1334.	1.5	94
77	An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 389, 528-537.	13.7	94
78	Patient-relevant treatment goals in psoriasis. Archives of Dermatological Research, 2016, 308, 69-78.	1.9	92
79	Treatment goals in psoriasis. JDDG - Journal of the German Society of Dermatology, 2007, 5, 566-574.	0.8	90
80	Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: A multicenter study. JDDG - Journal of the German Society of Dermatology, 2007, 5, 209-218.	0.8	87
81	Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. Journal of the American Academy of Dermatology, 2017, 76, 441-448.e2.	1.2	86
82	Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled <sc>TRANSFIGURE</sc> trial. British Journal of Dermatology, 2019, 181, 954-966.	1.5	84
83	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 281-317.	2.4	84
84	The genetic basis for most patients with pustular skin disease remains elusive. British Journal of Dermatology, 2018, 178, 740-748.	1.5	82
85	Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). British Journal of Dermatology, 2018, 178, 674-681.	1.5	80
86	Gender and age significantly determine patient needs and treatment goals in psoriasis – a lesson for practice. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 700-708.	2.4	78
87	The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. Journal of the American Academy of Dermatology, 2020, 83, 839-846.	1.2	78
88	Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study. Journal of the American Academy of Dermatology, 2019, 80, 70-79.e3.	1.2	77
89	Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 3-14.	2.4	76
90	Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 1670-1675.	2.4	75

#	ARTICLE	IF	CITATIONS
91	A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. <i>British Journal of Dermatology</i> , 2009, 160, 170-176.	1.5	73
92	IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. <i>Lancet</i> , The, 2021, 397, 1564-1575.	13.7	73
93	Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 936-945.	1.2	71
94	Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2437-2446.e1.	0.7	70
95	Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. <i>British Journal of Dermatology</i> , 2018, 179, 1205-1207.	1.5	69
96	Calcium spirulan derived from <i>Spirulina platensis</i> inhibits herpes simplex virus 1 attachment to human keratinocytes and protects against herpes labialis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 197-203.e3.	2.9	68
97	S3 - Guidelines on the treatment of psoriasis vulgaris Update 2011. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, S1-S95.	0.8	66
98	Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 977-987.e14.	2.9	66
99	Efficacy and safety of mirikizumab (<sc>LY</sc> 3074828) in the treatment of moderate to severe plaque psoriasis: results from a randomized phase <sc>II</sc> study. <i>British Journal of Dermatology</i> , 2019, 181, 88-95.	1.5	65
100	Quality of psoriasis care in Germany – results of the national study PsoHealth 2007. <i>JDDG - Journal of the German Society of Dermatology</i> , 2008, 6, 640-645.	0.8	63
101	Non-adherence and measures to improve adherence in the topical treatment of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 4-9.	2.4	63
102	The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2011, 12, 321-337.	6.7	62
103	Anxiety and depression in patients with moderate to severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1940-1949.	2.4	62
104	Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1707-1718.e9.	0.7	62
105	Psoriasis – New Insights Into Pathogenesis and Treatment. <i>Deutsches A&#x0308;rztblatt International</i> , 2009, 106, 11-8, quiz 19.	0.9	61
106	Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate to severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (<sc>UNCOVER</sc> 1, <sc>UNCOVER</sc> 2 and <sc>UNCOVER</sc> 3). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1686-1692.	2.4	60
107	In touch with psoriasis: topical treatments and current guidelines. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 3-8.	2.4	59
108	Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders. <i>JAMA Dermatology</i> , 2021, 157, 691.	4.1	59

#	ARTICLE	IF	CITATIONS
109	Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. <i>British Journal of Dermatology</i> , 2018, 179, 615-622.	1.5	57
110	Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized <scp>VOYAGE</scp> 1 and <scp>VOYAGE</scp> 2 studies. <i>British Journal of Dermatology</i> , 2019, 180, 1039-1049.	1.5	57
111	Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study. <i>Dermatology and Therapy</i> , 2021, 11, 571-585.	3.0	55
112	Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*. <i>British Journal of Dermatology</i> , 2021, 185, 323-334.	1.5	55
113	Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. <i>British Journal of Dermatology</i> , 2014, 170, 591-598.	1.5	51
114	Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. <i>Dermatology and Therapy</i> , 2020, 10, 133-150.	3.0	51
115	Improvement of treatment-refractory atopic dermatitis by immunoabsorption: A pilot study. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 267-270.e6.	2.9	50
116	Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 333-339.	2.4	50
117	Once-Weekly Administration of Etanercept 50 mg Improves Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis. <i>Dermatology</i> , 2009, 219, 239-249.	2.1	48
118	Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial. <i>British Journal of Dermatology</i> , 2017, 177, 1024-1032.	1.5	48
119	The German National Program on Psoriasis Health Care 2005-2015: results and experiences. <i>Archives of Dermatological Research</i> , 2016, 308, 389-400.	1.9	47
120	Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2017, 176, 752-758.	1.5	47
121	Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 397-402.	2.4	47
122	The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. <i>Archives of Dermatological Research</i> , 2008, 300, 537-544.	1.9	45
123	Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study. <i>British Journal of Dermatology</i> , 2011, 165, 399-406.	1.5	45
124	Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: Results from PHOENIX 2. <i>Journal of Dermatological Treatment</i> , 2011, 22, 337-347.	2.2	44
125	Strategies for improving the quality of care in psoriasis with the use of treatment goals - a report on an implementation meeting. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1-13.	2.4	44
126	Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 373-381.	2.4	44

#	ARTICLE	IF	CITATIONS
127	Evaluation of Quality of Care and Guideline-Compliant Treatment in Psoriasis. <i>Dermatology</i> , 2009, 219, 54-58.	2.1	42
128	Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients. <i>British Journal of Dermatology</i> , 2019, 181, 358-365.	1.5	42
129	Quality of psoriasis care in Germany: results of the national health care study "PsoHealth3". <i>Archives of Dermatological Research</i> , 2016, 308, 401-408.	1.9	41
130	Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2168-2173.	0.7	41
131	Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis*. <i>British Journal of Dermatology</i> , 2022, 186, 466-475.	1.5	41
132	Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). <i>Journal of Dermatological Treatment</i> , 2017, 28, 282-287.	2.2	40
133	Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2305-2312.	2.4	40
134	Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. <i>Dermatology and Therapy</i> , 2020, 10, 431-447.	3.0	40
135	Nail psoriasis as a severity indicator: results from the PsoReal study. <i>Patient Related Outcome Measures</i> , 2011, 2, 1.	1.2	38
136	Assessing adherence factors in patients under topical treatment: development of the Topical Therapy Adherence Questionnaire (TTAQ). <i>Archives of Dermatological Research</i> , 2014, 306, 287-297.	1.9	38
137	One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2014, 170, 435-444.	1.5	37
138	Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 30 Phase III VOYAGE 1 and VOYAGE 2 Studies. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 155-164.	6.7	37
139	A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP). <i>British Journal of Dermatology</i> , 2017, 177, 197-205.	1.5	36
140	Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study*. <i>British Journal of Dermatology</i> , 2021, 184, 425-436.	1.5	36
141	Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2*. <i>British Journal of Dermatology</i> , 2021, 185, 1146-1159.	1.5	36
142	Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data. <i>Acta Dermato-Venereologica</i> , 2022, 102, adv00698.	1.3	34
143	The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1196-1207.	2.4	33
144	Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1483-1490.	2.4	33

#	ARTICLE	IF	CITATIONS
145	Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label <scp>OPTIMISE</scp> study. British Journal of Dermatology, 2020, 182, 304-315.	1.5	33
146	Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1161-1173.	2.4	32
147	Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). British Journal of Dermatology, 2022, 187, 338-352.	1.5	32
148	A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment. British Journal of Dermatology, 2020, 182, 869-879.	1.5	31
149	IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open, 2021, 11, e049822.	1.9	31
150	COVID-19 and implications for dermatological and allergological diseases. JDDG - Journal of the German Society of Dermatology, 2020, 18, 815-824.	0.8	30
151	Mouse models of atopic dermatitis: a critical reappraisal. Experimental Dermatology, 2021, 30, 319-336.	2.9	30
152	Therapie der Psoriasis im Kindes- und Jugendalter - ein deutscher Experten-Konsens. JDDG - Journal of the German Society of Dermatology, 2011, 9, 815-824.	0.8	29
153	Deutsches Psoriasis-Register PsoBest: Zielsetzung, Methodik und Basisdaten. JDDG - Journal of the German Society of Dermatology, 2014, 12, 48-58.	0.8	29
154	Treatment goals in psoriasis routine care. Archives of Dermatological Research, 2015, 307, 445-449.	1.9	29
155	Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 546-552.	2.4	29
156	What is new in topical therapy for psoriasis?. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 15-20.	2.4	28
157	Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. European Journal of Dermatology, 2007, 17, 381-6.	0.6	28
158	Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis. British Journal of Dermatology, 2017, 177, 879-881.	1.5	26
159	Use of fumaric acid esters in psoriasis. Indian Journal of Dermatology, Venereology and Leprology, 2007, 73, 133.	0.6	26
160	Immunologic Effects and Tolerability Profile of In-Season Initiation of a Standardized-Quality Grass Allergy Immunotherapy Tablet: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial in Adults with Grass Pollen-Induced Rhinoconjunctivitis. Clinical Therapeutics, 2011, 33, 828-840.	2.5	25
161	Panimmunoglobulin and IgE-selective extracorporeal immunoadsorption in patients with severe atopic dermatitis. Journal of Allergy and Clinical Immunology, 2016, 137, 1882-1884.e6.	2.9	25
162	Psoriasis and metabolic syndrome in children: current data. Clinical and Experimental Dermatology, 2017, 42, 131-136.	1.3	25

#	ARTICLE	IF	CITATIONS
163	Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management. <i>British Journal of Dermatology</i> , 2018, 179, 1385-1391.	1.5	25
164	Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1521-1530.	2.2	25
165	Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT). <i>British Journal of Dermatology</i> , 2014, 170, 425-434.	1.5	24
166	Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 881-890.	6.7	24
167	Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. <i>British Journal of Dermatology</i> , 2020, 182, 180-189.	1.5	22
168	Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial*. <i>British Journal of Dermatology</i> , 2022, 186, 942-954.	1.5	22
169	Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventonal registry study*. <i>British Journal of Dermatology</i> , 2021, 185, 1160-1168.	1.5	21
170	Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study. <i>British Journal of Dermatology</i> , 2021, 185, 1124-1134.	1.5	21
171	Ustekinumab. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 355-356.	46.4	20
172	Development of an adherence-enhancing intervention in topical treatment termed the topical treatment optimization program (TTOP). <i>Archives of Dermatological Research</i> , 2014, 306, 667-676.	1.9	20
173	Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1156-1163.	2.4	20
174	Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1733-1741.	2.4	20
175	Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. <i>British Journal of Dermatology</i> , 2020, 182, 1359-1368.	1.5	20
176	Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1652-1660.	2.2	20
177	German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm "Part 2: Treatment monitoring and specific clinical or comorbid situations. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1092-1115.	0.8	20
178	Retrospective data collection of psoriasis treatment with fumaric acid esters in children and adolescents in Germany (KIDS FUTURE study). <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 50-57.	0.8	19
179	Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1098-1106.	2.4	19
180	A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque Psoriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2566-2573.	2.4	19

#	ARTICLE	IF	CITATIONS
181	Genetische Diagnostik bei entzündlichen Dermatosen - vom Einblick in die Pathophysiologie zur Möglichkeit eines individualisierten Managements. JDDG - Journal of the German Society of Dermatology, 2013, 11, 60-68.	0.8	18
182	Evaluation of adherence predictors for the treatment of moderate to severe psoriasis with biologics: the importance of physician-patient interaction and communication. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1014-1020.	2.4	18
183	Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1693-1699.	2.4	18
184	Quality of psoriasis care in Germany - results from the nationwide health care studies PsoHealth 2004-2017. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1536-1542.	2.4	18
185	Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey. Dermatology and Therapy, 2022, 12, 61-78.	3.0	18
186	Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care. PLoS ONE, 2020, 15, e0235091.	2.5	17
187	Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials. Journal of Dermatological Treatment, 2022, 33, 219-228.	2.2	17
188	Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. Journal of Dermatological Treatment, 2022, 33, 2317-2324.	2.2	17
189	An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals. British Journal of Dermatology, 2013, 168, 374-380.	1.5	16
190	Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies. British Journal of Dermatology, 2021, 184, 640-651.	1.5	16
191	Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study*. British Journal of Dermatology, 2021, 184, 849-856.	1.5	16
192	Consistency of Infliximab Response across Subgroups of Patients with Psoriasis: Integrated Results from Randomized Clinical Trials. Psoriasis Forum, 2007, 13a, 21-27.	0.1	15
193	The interpretation of long-term trials of biologic treatments for psoriasis: trial designs and the choices of statistical analyses affect ability to compare outcomes across trials. British Journal of Dermatology, 2013, 169, 1198-1206.	1.5	15
194	Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). British Journal of Dermatology, 2021, 184, 652-662.	1.5	15
195	Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 919-927.	2.4	15
196	Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis. American Journal of Clinical Dermatology, 2022, 23, 1-11.	6.7	15
197	Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 450-457.	2.4	14
198	Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis. Dermatology and Therapy, 2021, 11, 1965-1998.	3.0	14

#	ARTICLE	IF	CITATIONS
199	Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL). <i>Dermatology and Therapy</i> , 2020, 10, 1099-1109.	3.0	13
200	Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 329-337.	2.4	13
201	A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 701-711.	2.4	13
202	Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values 1, 2, 3 or 5 derived from a statistical conversion method. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1161-1175.	2.4	13
203	A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2045-2050.	2.4	13
204	The Validated Investigator Global Assessment for Atopic Dermatitis (VIGA-AD _v): a clinical outcome measure for the severity of atopic dermatitis. <i>British Journal of Dermatology</i> , 2022, 187, 531-538.	1.5	13
205	Drug supply for children with psoriasis in Germany. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 751-755.	0.8	12
206	Treatment Satisfaction in Psoriasis: Development and Use of the PsoSat Patient Questionnaire in a Cross-Sectional Study. <i>Dermatology</i> , 2016, 232, 334-343.	2.1	12
207	Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 294-303.	2.4	12
208	Methods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis Therapies: Implications for Interpretations of Trial Results. <i>Journal of Drugs in Dermatology</i> , 2017, 16, 734-741.	0.8	12
209	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 561.	4.1	12
210	Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations. <i>British Journal of Dermatology</i> , 2017, 177, 587-590.	1.5	10
211	Exposure-Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1489-1500.	2.0	10
212	Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab. <i>Journal of Dermatological Treatment</i> , 2020, 31, 617-623.	2.2	10
213	Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care. <i>European Journal of Dermatology</i> , 2020, 30, 267-278.	0.6	10
214	FRIO460...Secukinumab Shows Significant Efficacy in Nail Psoriasis: Week 32 Results from The Transfigure Study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 603.2-604.	0.9	9
215	Retrospektive Datenerhebung der Psoriasis-Behandlung mit Fumarsäureestern bei Kindern und Jugendlichen in Deutschland (KIDS FUTURE-Studie). <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 50-58.	0.8	9
216	Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2. <i>Journal of Dermatology</i> , 2019, 46, 1141-1152.	1.2	9

#	ARTICLE	IF	CITATIONS
217	Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials. <i>Acta Dermato-Venereologica</i> , 2022, 102, adv00683.	1.3	9
218	Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO. <i>Dermatology and Therapy</i> , 2022, 12, 203-221.	3.0	9
219	Immunoglobulin Eâ€“Selective Immunoabsorption Reduces Peripheral and Skin-Bound Immunoglobulin E and Modulates Cutaneous IL-13 Expression in Severe Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2019, 139, 720-723.	0.7	8
220	Use of doseâ€“exposureâ€“response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2082-2086.	2.4	8
221	The value of subcutaneous vs. oral methotrexate: realâ€“world data from the German psoriasis registry PsoBest. <i>British Journal of Dermatology</i> , 2021, 184, 765-767.	1.5	8
222	Longâ€“term efficacy and safety of brodalumab in moderateâ€“toâ€“severe plaque psoriasis: a post hoc pooled analysis of AMAGINEâ€“2 and â€“3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1275-1283.	2.4	8
223	Contact sensitization to essential oils: <scp>IVDK</scp> data of the years 2010â€“2019. <i>Contact Dermatitis</i> , 2022, 87, 71-80.	1.4	8
224	Treatment adherence: a hurdle for realâ€“life effectiveness in psoriasis?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1-3.	2.4	7
225	Continued treatment with secukinumab is associated with high retention or regain of response. <i>British Journal of Dermatology</i> , 2019, 182, 67-75.	1.5	7
226	Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1 and 17 inflammatory pathways. <i>British Journal of Dermatology</i> , 2019, 181, 859-862.	1.5	7
227	Molecular diagnostics in dermatology: An online survey to study usage, obstacles and requirements in Germany. <i>JDDG - Journal of the German Society of Dermatology</i> , 2022, 20, 287-295.	0.8	7
228	Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINEâ€“2 and AMAGINEâ€“3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2034-2044.	2.4	6
229	Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2409-2414.	2.4	6
230	The hair follicleâ€“psoriasis axis: Shared regulatory mechanisms and therapeutic targets. <i>Experimental Dermatology</i> , 2022, 31, 266-279.	2.9	6
231	Which PASI Outcome Is Most Relevant to the Patients in Real-World Care?. <i>Life</i> , 2021, 11, 1151.	2.4	6
232	Arzneimittelversorgung von Kindern mit Psoriasis in Deutschland. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 751-755.	0.8	5
233	Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Analysis from a Long-term Clinical Study. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2020, 13, 18-22.	0.1	5
234	Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderateâ€“toâ€“severe plaque psoriasis naïve to systemic treatment. <i>British Journal of Dermatology</i> , 2021, 184, 548-550.	1.5	4

#	ARTICLE	IF	CITATIONS
235	Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis. <i>Dermatology and Therapy</i> , 2022, 12, 233-241.	3.0	4
236	Switching from a fumaric acid ester mixture to dimethylfumarate monotherapy in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e352-e353.	2.4	3
237	15057 Safety of baricitinib in patients with atopic dermatitis: Results of pooled data from two phase 3 monotherapy randomized, double-blind, placebo-controlled 16-week trials (BREEZE-AD1 and Tj ETQq1 1 0.784314.rgBT /Overlock 10		
238	Measuring patient-relevant benefits in the treatment of psoriasis with the Patient Benefit Index: development and preliminary validation of a 10-item short form. <i>British Journal of Dermatology</i> , 2022, 187, 588-589.	1.5	3
239	Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence?. <i>British Journal of Dermatology</i> , 2022, 187, 591-593.	1.5	3
240	Genetic diagnostics in inflammatory dermatoses - from insights into pathophysiology to individualized patient management. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 59-67.	0.8	2
241	Comment on "Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis". <i>Journal of Investigative Dermatology</i> , 2017, 137, 2642-2644.	0.7	2
242	Correlation of Physician-Assessed Psoriasis Area and Severity Index Scores With Patient-Reported Psoriasis Symptoms and Signs Diary Scores Among Patients With Moderate-to-Severe Psoriasis: Results From VOYAGE 1 and VOYAGE 2 Studies. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 147-152.	0.7	2
243	Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. <i>Quality of Life Research</i> , 2020, 29, 369-380.	3.1	2
244	FRI0272...SECUKINUMAB DEMONSTRATES A CONSISTENT SAFETY PROFILE IN PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS OVER LONG TERM: UPDATED POOLED SAFETY ANALYSES. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 722.2-722.	0.9	2
245	Methods used for indirect comparisons of systemic treatments for psoriasis. A systematic review. <i>Skin Health and Disease</i> , 0, , .	1.5	2
246	Methotrexate therapy in dermatology. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 363-370.	0.8	1
247	OP0114...MACHINE LEARNING TOOLS IDENTIFY PATIENT CLUSTERS AND SWOLLEN AND TENDER JOINT CORRELATION PATTERNS IN A LARGE DATABASE FROM THE SECUKINUMAB PSORIATIC ARTHRITIS CLINICAL DEVELOPMENT PROGRAM. , 2019, , .		1
248	Transcriptomic Analysis of Blaschko-Linear Psoriasis Reveals Shared and Distinct Features with Psoriasis Vulgaris. <i>Journal of Investigative Dermatology</i> , 2021, , .	0.7	1
249	FRI0087...DURABILITY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS OR PSORIASIS OVER THREE YEARS: AN ANALYSIS OF POOLED CLINICAL TRIAL DATA. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 621.1-621.	0.9	1
250	Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analysis from phase 3 trials in patients with psoriatic arthritis. <i>British Journal of Dermatology</i> , 2022, , .	1.5	1
251	A new treatment option for paediatric psoriasis. <i>British Journal of Dermatology</i> , 2020, 183, 606-607.	1.5	0
252	POS1031...LOW INCIDENCE OF GASTROINTESTINAL-RELATED AND OVERALL SERIOUS ADVERSE EVENTS AMONG GUSELKUMAB-TREATED PATIENTS: POOLED ANALYSES OF VOYAGE 1 & 2 AND DISCOVER 1 & 2 THROUGH 1-YEAR. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 787-788.	0.9	0